GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Publisher： John Wiley & Sons Inc

E-ISSN： 1930-739x|23|6|1119-1129

ISSN： 1930-7381

Source： OBESITY, Vol.23, Iss.6, 2015-06, pp. : 1119-1129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The “dose” of exercise and its effects beyond weight loss

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1115-1117

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A.   Ballantine Jane  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?

By Peterson Gregory  

Annals of Medicine, Vol. 44, Iss. 4, 2012-06 ,pp. : 338-349

Informa Healthcare

Access to resources Recommend Favorite

A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 22-33

John Wiley & Sons Inc

Access to resources Recommend Favorite

GLP-1 receptor agonists and HBA1c target of <7%% in type 2 diabetes: meta-analysis of randomized controlled trials

By Esposito K.   Mosca C.   Brancario C.   Chiodini P.   Ceriello A.   Giugliano D.  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1519-1528

Informa Healthcare

Access to resources Recommend Favorite